ArticleClinical journal of gastroenterology2025
Sustained effectiveness of balloon-occluded retrograde transvenous obliteration for portopulmonary hypertension after liver transplantation: a 5-year follow-up case report.
Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portopulmonary hypertension (POPH), a subtype of pulmonary arterial hypertension (PAH), develops with portal hypertension and may persist after liver transplantation. While there have been successes using balloon-occluded retrograde transvenous obliteration (BRTO) for POPH, no reports exist on long-term follow-up. A 60-year-old man with hepatitis C cirrhosis developed POPH. At the time POPH was diagnosed, the mean pulmonary artery pressure (mPAP) was 31 mmHg. After medical management, mPAP improved to 20 mmHg, and he underwent living-donor liver transplantation. Three years post-transplant, he presented with severe dyspnea and elevated mPAP of 67 mmHg. Despite pharmacological treatment for PAH, his symptoms and pulmonary pressures remained uncontrolled. After transplantation, the pre-existing splenorenal shunt expanded, suggesting that increased shunt blood flow contributed to worsening POPH. BRTO was performed after confirming that shunt occlusion did not elevate portal pressure. Post-procedure, his pulmonary pressures improved (mPAP, 25 mmHg), and symptoms resolved. Over 5 years, no recurrence of POPH, portal hypertension, or liver dysfunction occurred. This case demonstrates the long-term effectiveness of BRTO in treating POPH exacerbation post-liver transplantation. In cases of POPH following liver transplantation, portosystemic shunt occlusion via BRTO may be an effective strategy to improve POPH.
Indexed as
Identifiers
40924319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.